The ADS TUE Policy has been revised to include changes to the 2017 Prohibited List. The key revisions to the ADS TUE Policy is to Section 4 (Procedure for Asthma Treated with Beta-2 Agonists) on the refinements and guidelines for the thresholds of permitted Beta-2 Agonists for treatment of asthma.
